Experimental “enhancer” may boost conventional therapies for pediatric disease

Alexandra Miller named chief of neuro-oncology and co-director of Brain and Spine Tumor Center at NYU Perlmutter

Alexandra Miller, a neurologist and neuro-oncologist specializing in treating primary brain tumors, has been named as the chief of the Division of Neuro-Oncology and co-director of the Brain and Spine Tumor Center at NYU Langone Health’s Perlmutter Cancer Center, effective Jan. 29.

January 26, 2024

Vol.50 No.04

In Brief

Glenn Lesser named deputy director of the Atrium Health Wake Forest Baptist CCC

Glenn J. Lesser was named deputy director of the Atrium Health Wake Forest Baptist Comprehensive Cancer Center.

December 01, 2023

Vol.49 No.44

Letter To The Editor

“Field of Dread” (continued): Do “forever chemicals” in AstroTurf cause GBM?

A letter to the editor by The Philadelphia Inquirer’s James Neff raises concerns about conflicts of interest in a recent Guest Editorial published in The Cancer Letter. The authors and The Cancer Letter editor respond.

October 27, 2023

Vol.49 No.40

Clinical Roundup

Telomere-targeting agent demonstrates potent anticancer activity in aggressive pediatric brain cancer in preclinical study

Study data from MAIA Biotechnology, Inc. showed that THIO (6-thio-dG or 6-thio-2’-deoxyguanosine), a first-in-class investigational telomere-targeting agent, demonstrates potent anticancer activity in diffuse intrinsic pontine glioma, one of the most aggressive tumors affecting the central nervous system in children.

October 13, 2023

Vol.49 No.38

In Brief

UCLA researchers awarded $2.5M from DoD to develop brain cancer treatment

A multidisciplinary team of investigators from the UCLA Jonsson Comprehensive Cancer Center was awarded a $2.5 million Translational Team Science Award from the Department of Defense to develop a tailored treatment for glioblastoma, a deadly brain tumor with limited treatment options.

September 15, 2023

Vol.49 No.34

Clinical Roundup

Investigators devise test to identify brain tumors from cerebrospinal fluid

Researchers with the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine and four other institutions have developed a molecular test to identify the presence of brain tumors by measuring abnormal genetic material shed by tumors and circulating in cerebrospinal fluid.

September 15, 2023

Vol.49 No.34

Experimental “enhancer” may boost conventional therapies for pediatric disease

YOU MAY BE INTERESTED IN

Alexandra Miller named chief of neuro-oncology and co-director of Brain and Spine Tumor Center at NYU Perlmutter

Glenn Lesser named deputy director of the Atrium Health Wake Forest Baptist CCC

“Field of Dread” (continued): Do “forever chemicals” in AstroTurf cause GBM?

Telomere-targeting agent demonstrates potent anticancer activity in aggressive pediatric brain cancer in preclinical study

UCLA researchers awarded $2.5M from DoD to develop brain cancer treatment

Investigators devise test to identify brain tumors from cerebrospinal fluid

Renew today!

Subscriber content

Login